Virtual Meetings 2022

Meet The Professor: Optimizing the Management of Multiple Myeloma

For an up-to-date schedule of upcoming sessions in this series, please click here.

PARTICIPATING FACULTY

Shaji K Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia



Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul G Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by educational grants from AbbVie Inc, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for multiple myeloma. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma

    MODULE 2: Integration of Novel Therapies into the Treatment of Relapsed/Refractory Disease

    MODULE 3: Incorporation of CAR (Chimeric Antigen Receptor) T-Cell Therapy into the Care of Patients with Multiple Myeloma

    MODULE 4: Novel Investigational Agents for Multiple Myeloma

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of multiple myeloma.

Learning Objectives

  • Customize the selection of first-line therapy for newly diagnosed multiple myeloma (MM), considering new clinical research findings and patient- and disease-related factors such as cytogenetic profile and fitness for stem cell transplantation.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM who are eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies in order to facilitate their integration into MM management algorithms.
  • Evaluate the biologic rationale for the use of CAR (chimeric antigen receptor) T-cell therapy directed at BCMA (B-cell maturation antigen) as a targeted therapeutic strategy in MM, and identify patients for whom this novel approach should be considered.
  • Recall the design and rationale of ongoing clinical trials evaluating novel agents and strategies (eg, BiTEs, venetoclax) for MM, including emerging data, and counsel appropriate patients about availability and participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Raje has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr KumarAdvisory Committee: AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Consulting Agreements (No Personal Payments): AbbVie Inc, Amgen Inc, Arcellx, AstraZeneca Pharmaceuticals LP, bluebird bio, Bristol-Myers Squibb Company, Epizyme Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, K36 Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Monte Rosa Therapeutics, Sanofi Genzyme, Secura Bio, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Consulting Agreements (with Personal Payments): Antengene, BeiGene Ltd, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Janssen Biotech Inc; Research Funding for Clinical Trials to the Institution: AbbVie Inc, Allogene Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc. Dr LonialAdvisory Committee: AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc; Board of Directors with Stock: TG Therapeutics Inc; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Novartis, Takeda Pharmaceuticals USA Inc. Dr RichardsonAdvisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Protocol Intelligence, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Secura Bio, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Karyopharm Therapeutics, Oncopeptides, Takeda Pharmaceuticals USA Inc.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AbbVie Inc, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Karyopharm Therapeutics.